Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3809169 | Medicine - Programa de Formación Médica Continuada Acreditado | 2015 | 7 Pages |
Abstract
Alzheimer's disease (AD) is a chronic progressive neurodegenerative process that involves considerable suffering. The etiopathogenic context is complex and the physical and social environments are usually fragile, so all therapeutic efforts must be framed to slowing down the course of the disease and improve quality of life (QoL). Care is based on the treatment of medical comorbidity, prevention and management of psychological and behavioral problems, specific the pharmacological treatment and information, advice and ongoing support for both the patient and caregiver. Cholinesterase inhibitor drugs (ICE) and memantine delay cognitive decline and improve apathy and psychotic symptoms. Non-pharmacological therapies provide additional and complementary benefits in areas where drugs are usually less effective (emotions, behavior and QoL). There are several lines of pharmacological research for AD that could delay the onset of dementia or prolong the milder stages of the disease.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
D. Sánchez, N. Bravo, J. Miranda, J. Olazarán,